Gastrointestinal Cancers

Fear of nuclear fallout has led to a novel therapeutic approach that could significantly extend the lives of individuals with pancreatic cancer or other gastrointestinal malignancies.

Cancer diagnoses fell significantly below expectations in 2020 due to the COVID-19 pandemic but recovered to projected levels the following year, according to results of a cross-sectional study.

Most cancer clinical trials use inaccurate tests to evaluate kidney function when determining participant eligibility, according to results of a cross-sectional study.

In this episode, host Shikha Jain, MD, speaks with David Cosgrove, MD, about implementing real-world utilization of clinical trials, the importance of diversity in clinical trials and more.

The commonly used diabetes drug metformin may reduce risk for cancer, according to study results published in Journal of the National Cancer Institute.

In this episode, host Shikha Jain, MD, speaks with Christina Gomez, MD, about the power of patients’ voices, finding joy in physicians' work-life balance and more.

High-risk gastrointestinal cancer diagnoses declined sharply during the first 3 months of the COVID-19 pandemic in 2020, but they returned to previous levels by the middle of the year, according to results published in JAMA Network Open.

Each year, the first Friday in March kicks off Colorectal Cancer Awareness Month with National Dress in Blue Day, a campaign aimed at increasing visibility, raising awareness and honoring those impacted by this highly preventable disease.

In this video, Rachna T. Shroff, MD, MS, discusses updated data on tinengotinib, presented at ASCO Gastrointestinal Cancers Symposium.

Circulating tumor DNA did not successfully predict whether patients with resected stage II colon cancer would benefit from adjuvant chemotherapy, according to findings presented at ASCO Gastrointestinal Cancers Symposium.